Ryan DeMasi

1.9k citations

30 papers · 1.1k indexed · 1 hit paper · h-index 14

Impact in

Rheumatology top 1%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
Hematology top 2%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 29
- Rheumatoid Arthritis Research and Therapies 29
- Systemic Lupus Erythematosus Research 5
- Spondyloarthritis Studies and Treatments 2
Hematology 19
- Autoimmune and Inflammatory Disorders Research 19

Co-authors: Kenneth Kwok Lisy Wang Stanley Cohen Jeffrey R. Curtis J. Wollenhaupt Christina Charles‐Schoeman Koshika Soma Yoshiya Tanaka
Journals: Annals of the Rheumatic Diseases (15 papers)RMD Open (2 papers)Lara D. Veeken (2 papers)Arthritis Care & Research (2 papers)Modern Rheumatology (1 paper)
Partner nations: United States United Kingdom Germany

In The Last Decade

Ryan DeMasi

30 papers receiving 1.0k citations

Hit Papers

align trajectories log scale

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials 2017 · 302 citations

Peers

Countries citing papers authored by Ryan DeMasi

Since Specialization

Citations

This map shows the geographic impact of Ryan DeMasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan DeMasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan DeMasi more than expected).

Fields of papers citing papers by Ryan DeMasi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan DeMasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan DeMasi. The network helps show where Ryan DeMasi may publish in the future.

Co-authors

The 25 scholars most cited alongside Ryan DeMasi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ryan DeMasi Line = papers co-authored together Ryan DeMasi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	POS0683 EFFICACY AND SAFETY OF UPADACITINIB IN TNFi-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS Annals of the Rheumatic Diseases ·Roy Fleischmann, Louis Bessette, J. Mackowiak, Francisco A. Quiroz y Ferrari, Pedro Pablo Troncoso González, Adriana María Kakehasi, Wei‐Qi Yan, Sebastian Meerwein, Ryan DeMasi, Deppmeyer, Andrea Rubbert‐Roth	2022	2
2	POS0653 IMPACT OF UPADACITINIB OR ADALIMUMAB AS INITIAL THERAPY ON THE ACHIEVEMENT OF 48-WEEK TREATMENT GOALS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: POST HOC ANALYSIS OF A PHASE 3 STUDY Annals of the Rheumatic Diseases ·Eduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, Daniel Aletaha, Peter C. Taylor, In Ho Song, T. Shaw, V. Mozaffari, Ryan DeMasi, Mohammed Ali, Roy Fleischmann	2021	2
3	Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis Annals of the Rheumatic Diseases ·Roy Fleischmann, Ricardo Blanco, Stephen Hall, G. T. D. Thomson, Filip Van den Bosch, Cristiano A. F. Zerbini, Louis Bessette, Francis Fukuyama, Yihan Li, Paul Kivel, Ryan DeMasi, In‐Ho Song	2020	19
4	Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis Clinical Rheumatology ·Jeffrey Kaine, John Tesser, Liza Takiya, Ryan DeMasi, Lisy Wang, Renato Lira Brito, Koshika Soma, Haiyun Fan, Gregory P. Haake, J. Wollenhaupt	2020	13
5	Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study Arthritis Research & Therapy ·J. Wollenhaupt, R. Blok, Jeffrey R. Curtis, Joel C. Silverfield, Ketti K. Terry, Koshika Soma, Ben Jensen, Ryan DeMasi, Sander Strengholt, Kenneth Kwok, Irina Lazariciu, Lisy Wang, Stanley Cohen	2019	238
6	Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis Arthritis & Rheumatology ·Christina Charles‐Schoeman, Ryan DeMasi, Hernán Valdez, Koshika Soma, Lie‐Ju Hwang, M. Boy, Pinaki Biswas, Iain B. McInnes	2019	63
7	Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies Arthritis Care & Research ·Dafna D. Gladman, Christina Charles‐Schoeman, Iain B. McInnes, Douglas J. Veale, B.H. Thiers, Michael T. Nurmohamed, D. Graham, Cunshan Wang, Thomas V. Jones, Robert Wołk, Ryan DeMasi	2019	38
8	Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis Rheumatology and Therapy ·Stanley Cohen, Jeffrey R. Curtis, Ryan DeMasi, Yan Chen, Haiyun Fan, Re‐Yang Lee, Roy Fleischmann	2018	60
9	The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review Drug Safety ·Michael T. Nurmohamed, Ernest Choy, Sadiq Lula, Blerina Kola, Ryan DeMasi, Jácome-Burgos Alfredo	2018	28
10	Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review Advances in Therapy ·Paul Emery, Janet Pope, Klaus Krüger, Ralph Lippe, Ryan DeMasi, Sadiq Lula, Blerina Kola	2018	62
11	SAT0243 Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes Annals of the Rheumatic Diseases ·Philip J. Mease, Joel M. Kremer, Stanley Cohen, Jeffrey R. Curtis, Christina Charles‐Schoeman, Edward V. Loftus, 邢维凯, Swapna Armoor, Тетяна Шалацька, D. Graham, C. Wang, Pinaki Biswas, Gary Chan, Ryan DeMasi, Hernán Valdez, Thijs Hendrikx, Thomas V. Jones	2018	7
12	Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6 Arthritis Care & Research ·Ronald van Vollenhoven, Eun Bong Lee, Lara Fallon, Samuel H. Zwillich, Bethanie Wilkinson, Douglass Chapman, Ryan DeMasi, Edward Keystone	2018	8
13	SAT0256 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a phase 3b/4 randomised trial Annals of the Rheumatic Diseases ·Vibeke Strand, Eduardo Mysler, Robert J. Moots, Gene V. Wallenstein, Ryan DeMasi, David Gruben, 張育愷, Noriko Iikuni, Roy Fleischmann	2018	2
14	SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years Annals of the Rheumatic Diseases ·J. Wollenhaupt, Joel C. Silverfield, 박주호, Ketti K. Terry, Kenneth Kwok, Sander Strengholt, Ryan DeMasi, Muzaffarjon Abdulakhatov	2018	22
15	OP0037 Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: analysis of data from open-label long-term extension studies Annals of the Rheumatic Diseases ·Jeffrey Kaine, John Tesser, Ryan DeMasi, Liza Takiya, Muzaffarjon Abdulakhatov, 克己入江, Heng Fan, Gregory P. Haake, J. Wollenhaupt	2018	5
16	Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years Arthritis & Rheumatism ·D. van der Heijde, J. Wollenhaupt, Stanley Cohen, Sander Strengholt, Ketti K. Terry, Ryan DeMasi, Kenneth Kwok, Irina Lazariciu, Dana Vesty	2017	3
17	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials Annals of the Rheumatic Diseases ·Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R. Curtis, Eun Bong Lee, Peter Nash, Kevin Winthrop, Christina Charles‐Schoeman, Krishan Thirunavukkarasu, Ryan DeMasi, Jamie Geier, Kenneth Kwok, Lisy Wang, Richard J. Riese, J. Wollenhaupt Hit paper breakdown →	2017	302
18	THU0211 Meta-analysis of serious infections with baricitinib, tofacitinib and biologic dmards in rheumatoid arthritis Annals of the Rheumatic Diseases ·Vibeke Strand, Sima Ahadieh, Ryan DeMasi, S. Krishnaswami, Jamie Geier, Sujatha Menon, Jennifer L. Newell-Caito	2017	7
19	Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies Lara D. Veeken ·Hendrik Schulze‐Koops, Vibeke Strand, Chudy I. Nduaka, Ryan DeMasi, Gene V. Wallenstein, Kenneth Kwok, Lisy Wang	2016	69
20	Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data Journal of Antimicrobial Chemotherapy ·Mark Nelson, Pierre‐Marie Girard, Ryan DeMasi, Lei Chen, Maria Emanuella Mariani Dula, Jorge P Yánez, Ludo Lavreys	2010	37

About Ryan DeMasi

Ryan DeMasi is a scholar working on Rheumatology, Hematology, Genetics, Immunology and Pathology and Forensic Medicine, having authored 30 papers that have together received 1.1k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (29 papers), Autoimmune and Inflammatory Disorders Research (19 papers), Chronic Lymphocytic Leukemia Research (9 papers), Biosimilars and Bioanalytical Methods (5 papers), Systemic Lupus Erythematosus Research (5 papers), Lymphoma Diagnosis and Treatment (3 papers), Acute Lymphoblastic Leukemia research (2 papers) and Spondyloarthritis Studies and Treatments (2 papers). The work is most often cited by research in Rheumatology (752 citations), Hematology (387 citations), Genetics (163 citations), Immunology (226 citations) and Oncology (236 citations). Ryan DeMasi has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Kenneth Kwok, Lisy Wang, Stanley Cohen, Jeffrey R. Curtis, J. Wollenhaupt, Christina Charles‐Schoeman, Koshika Soma, Yoshiya Tanaka, Ketti K. Terry and Joel C. Silverfield. Their work appears in journals such as Annals of the Rheumatic Diseases, RMD Open, Lara D. Veeken, Arthritis Care & Research and Modern Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact